Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is expected to see strong revenue growth in the coming years due to its enhanced contracts and a growing pipeline of new contracts. This, combined with cost-saving measures and a potential for multiple expansion, could drive the company's profitability and stock price higher in the future. While there are potential risks, such as customer concentration and rising healthcare costs, the company has strategies in place to mitigate these risks and maintain its competitive advantage. Additionally, the recent announcement of two new contracts and successful implementations with key partners demonstrate the strong execution of Evolent's growth plans.

Bears say

Evolent Health is currently trading at a premium compared to other payors and health systems, but its aggressive growth strategy and high barrier to entry could lead to a potential valuation floor of $5 per share. With a diversified portfolio of services and a focus on value-based care and population health management, Evolent has the potential for long-term growth and strong partnerships. However, there are also potential risks with its approach, such as underperformance in the short-term due to conservative posture and potential regulatory changes. Despite these risks, as long as Evolent continues its growth trajectory, it may provide opportunities for strong returns in the future.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.